Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

PURPOSE: Based on promising predinical data, we conducted a single-arm phase II trial to assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/PR) or stable disease (SD) ≥24 weeks, in HER2(mut) nonamplified metastatic breast cancer (MBC). Secondary endpoints i...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Cancer Res
Glavni autori: Ma, Cynthia X., Bose, Ron, Gao, Feng, Freedman, Rachel A., Telli, Melinda L., Kimmick, Gretchen, Winer, Eric, Naughton, Michael, Goetz, Matthew P., Russell, Christy, Tripathy, Debu, Cobleigh, Melody, Forero, Andres, Pluard, Timothy J., Anders, Carey, Niravath, Polly Ann, Thomas, Shana, Anderson, Jill, Bumb, Caroline, Banks, Kimberly C., Lanman, Richard B., Bryce, Richard, Lalani, Alshad S., Pfeifer, John, Hayes, Daniel F., Pegram, Mark, Blackwell, Kimberly, Bedard, Philippe L., Al-Kateb, Hussam, Ellis, Matthew J.C.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6746403/
https://ncbi.nlm.nih.gov/pubmed/28679771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0900
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items